Psychedelic biotechs are moving towards Phase 3 with five companies advancing CNS treatments for depression and anxiety.

Helus Pharma, in Vancouver, BC, issued a statement on February 27, 2026, reporting that psychedelic compounds are making progress towards regulatory approval. Pivotal trials in treating depression and anxiety that have not responded to traditional treatments are moving forward in late-stage development. These achievements are significant for the mental health industry, showcasing potential breakthroughs in alternative therapies. The innovations in treatment come as a response to the ineffectiveness of current treatments on individuals with depression and anxiety. The progress offers hope for those who have not found relief through conventional methods. Such advancements in psychedelic compounds highlight the changing landscape of mental health care and may lead to new, effective options for patients.